glp-1 bmi 25 A Balancing Act: Receptor Agonists for Non-Diabetic Obesity – Clinical Correlations P181 Glucagon-like peptide-1 receptor agonist

Freland L, Beaulieu JM

Why this matters: Eliminates the need for injection Non-peptide structure A CMC & Innovation Perspective: Transitioning GLP-1 therapies from peptide injectables to oral small molecules reflects a paradigm shift in: Drug design & stability Supply chain efficiency Cost of goods & scalability Role of CMC Competitive Intelligence: Benchmarking against injectable GLP-1s

As a result, scientists are now trialing these drugs as treatments for substance use disorders

Protocol 1: essential foundation (everyone should consider this) Goal: Prevent the most common nutrient deficiencies during GLP-1 therapy

However, it's important to note that these studies involved individuals with type 2 diabetes, and the dosages of the two medications were not equal

What started as a treatment for type 2 diabetes has rapidly evolved into a platform therapy influencing obesity, cardiovascular disease, fatty liver disease, neurodegeneration, inflammation, and potentially oncology